Patents by Inventor Ramesh S. Kashi
Ramesh S. Kashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230321234Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.Type: ApplicationFiled: March 10, 2023Publication date: October 12, 2023Applicant: Merck Sharp & Dohme LLCInventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
-
Publication number: 20230263887Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.Type: ApplicationFiled: March 10, 2023Publication date: August 24, 2023Applicant: Merck Sharp & Dohme LLCInventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
-
Patent number: 11633476Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.Type: GrantFiled: May 1, 2018Date of Patent: April 25, 2023Assignee: Merck Sharp & Dohme LLCInventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, Yogita Krishnamachari
-
Publication number: 20220378916Abstract: The present invention relates to pegylated amino acid compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution.Type: ApplicationFiled: June 29, 2022Publication date: December 1, 2022Applicant: Merck Sharp & Dohme LLCInventors: Lin Chu, Nathalie Y. Toussaint, Dong Xiao, Petr Vachal, Ramesh S. Kashi, Annette Bak
-
Publication number: 20210188964Abstract: The present invention provides high concentration solution formulations of anti-human interleukin-23 p19 (IL-23p19) antibody huml3B8-b, and their use in treating various disorders.Type: ApplicationFiled: December 8, 2020Publication date: June 24, 2021Inventors: Ramesh S. KASHI, Aniket BADKAR
-
Publication number: 20200206350Abstract: The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution.Type: ApplicationFiled: August 31, 2018Publication date: July 2, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Lin Chu, Nathalie Y. Toussaint, Dong Xiao, Petr Vachal, Ramesh S. Kashi, Annette Bak
-
Publication number: 20200147213Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.Type: ApplicationFiled: May 1, 2018Publication date: May 14, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, JR., Yogita Krishnamachari
-
Patent number: 9803010Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.Type: GrantFiled: June 25, 2013Date of Patent: October 31, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
-
Publication number: 20170216428Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.Type: ApplicationFiled: September 12, 2016Publication date: August 3, 2017Applicant: Agenus Inc.Inventors: Alemseged Truneh, Daniel L. Levey, Annie Xiaoyan Mo, Kenneth P. Leclair, Ramesh S. Kashi, Aston Chuanliang Liu
-
Patent number: 9649383Abstract: The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.Type: GrantFiled: November 15, 2013Date of Patent: May 16, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Ramesh S. Kashi, Shona P. Patel, Sarita Mittal, Ashwin Basarkar, Shuai Shi
-
Publication number: 20150329632Abstract: The present invention provides high concentration solution formulations of anti-human interleukin-23 p19 (IL-23p19) antibody hum13B8-b, and their use in treating various disorders.Type: ApplicationFiled: December 9, 2013Publication date: November 19, 2015Inventors: Ramesh S. KASHI, Aniket BADKAR
-
Publication number: 20150290325Abstract: The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.Type: ApplicationFiled: November 15, 2013Publication date: October 15, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Ramesh S. Kashi, Shona P. Patel, Sarita Mittal, Ashwin Basarkar, Shuai Shi
-
Publication number: 20150147337Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.Type: ApplicationFiled: June 25, 2013Publication date: May 28, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
-
Publication number: 20140105854Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.Type: ApplicationFiled: August 12, 2013Publication date: April 17, 2014Applicant: Agenus Inc.Inventors: Alemseged Truneh, Daniel L. Levey, Xiaoyan Mo, Kenneth P. Leclair, Ramesh S. Kashi, Chuanliang Liu
-
Patent number: 8541002Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.Type: GrantFiled: September 13, 2004Date of Patent: September 24, 2013Assignee: Agenus Inc.Inventors: Alemseged Truneh, Daniel L. Levey, Xiaoyan Mo, Kenneth P. Leclair, Ramesh S. Kashi, Chuanliang Liu
-
Patent number: 8263748Abstract: The present invention provides lyophilized formulations of antibodies, such as antibodies that specifically bind to human interleukin-23 p19 (IL-23p19), or antigen binding fragments thereof.Type: GrantFiled: August 25, 2009Date of Patent: September 11, 2012Assignee: Schering CorporationInventors: Xuhong Li, Ramesh S. Kashi, Aniket Badkar
-
Publication number: 20110229490Abstract: The present invention provides lyophilized formulations of antibodies, such as antibodies that specifically bind to human interleukin-23 p19 (IL-23p19), or antigen binding fragments thereof.Type: ApplicationFiled: August 25, 2009Publication date: September 22, 2011Applicant: Schering CorporationInventors: Xuhong Li, Ramesh S. Kashi, Aniket Badkar
-
Publication number: 20110059041Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.Type: ApplicationFiled: September 13, 2004Publication date: March 10, 2011Inventors: Alemseged Truneh, Daniel L. Levey, Xiaoyan Mo, Kenneth P. LeClair, Ramesh S. Kashi, Liu Chuanliang